Every 8-K that Synergy CHC Corp. (SNYR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SNYR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNYR filings page.
Synergy CHC Corp. (SNYR) reports that Nasdaq has moved to delist its common stock following the company’s recent Chapter 11 filing. The company received a Delisting Notice on September 11, 2026, stating that trading on Nasdaq will be suspended at the opening of business on September 18, 2026.
Nasdaq’s decision cites the Chapter 11 bankruptcy cases, public interest concerns, questions about residual equity value for current holders, and the company’s ability to sustain compliance with Nasdaq listing standards. Synergy CHC Corp. does not intend to appeal, and a Form 25-NSE is expected to remove its securities from Nasdaq listing.
Synergy CHC Corp. (SNYR) has filed a voluntary petition for relief under chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Columbia, placing the company’s assets under the court’s jurisdiction and establishing it as a debtor-in-possession.
The company states it reasonably anticipates filing a plan of liquidation or reorganization within a forthcoming 120-day period, and a meeting of creditors will be scheduled under the Bankruptcy Code and related rules. Synergy CHC Corp. has engaged The VerStandig Law Firm, LLC as counsel and advisor in the case. In connection with the restructuring, Lauren P. Berret of Eisner Advisory Group LLC was engaged as chief restructuring officer, and on September 4, 2026, immediately after the chapter 11 filing, four directors—Alfred Baumeler, Nitin Kaushal, J. Paul SoRelle and Teresa Thompson—resigned from the Board, leaving Jack Ross as the sole remaining director. Baumeler also resigned as President effective August 31, 2026.
Synergy CHC Corp. (SNYR) reports that its term loan lenders have accelerated the company’s debt. On August 25, 2026, ACP Agency, LLC, acting as administrative and collateral agent under Synergy’s Term Loan Credit Agreement dated May 30, 2025, issued a Notice of Acceleration.
According to the notice, all commitments under the credit facility have been terminated and all obligations outstanding under the credit agreement and related loan documents have been accelerated and declared immediately due and payable. As of August 21, 2026, approximately $18.9 million was immediately due and payable, excluding additional interest, fees, costs and expenses, which continue to accrue. The acceleration follows Events of Default previously disclosed by the company.
Synergy CHC Corp. (SNYR) reported that Nasdaq has notified the company it is not in compliance with Nasdaq Listing Rule 5250(c)(1) because its Quarterly Report on Form 10‑Q for the quarter ended June 30, 2026 has not been filed with the SEC. The notice currently has no immediate effect on the listing or trading of Synergy’s common stock on Nasdaq.
Synergy has 60 days from the August 20, 2026 notice to submit a compliance plan to Nasdaq, which may, at its discretion, grant up to 180 days from the Q2 Form 10‑Q due date for Synergy to regain compliance. The company states it is unable to predict when, or whether, the Q2 Form 10‑Q will be filed or whether it will regain compliance.
Synergy CHC Corp. reported that on August 11, 2026 it received a notice of default from ACP Agency, LLC under its Term Loan Credit Agreement dated May 30, 2025. ACP asserted an Event of Default occurred after Synergy failed to make the interest payment due on August 3, 2026, following expiration of the cure period on August 6, 2026. ACP also stated that the forbearance period under a Forbearance Agreement dated May 28, 2026 terminated on August 6, 2026 and that a forbearance fee of $404,173.06 is now payable. Approximately $17.6 million principal remains outstanding under the Credit Agreement, excluding accrued interest, fees and expenses. ACP has reserved all rights and remedies, including charging interest at a post-default rate and accelerating the loan obligations.
Synergy CHC Corp. reports that on July 15, 2026, Costco Wholesale Corporation informed the company it will discontinue carrying Synergy’s FOCUSfactor products. Costco has been a significant customer for more than 16 years and accounted for approximately 58% of net revenue for the fiscal year ended December 31, 2025.
The company expects Costco’s decision to have a material adverse effect on its business, results of operations, liquidity and financial condition, and is evaluating available financing and other strategic alternatives in response.
Synergy CHC Corp. reported the results of its 2026 annual stockholder meeting. Stockholders approved amending the 2024 Equity Incentive Plan to increase the pool to 150,000,000 common shares and allow repricing of outstanding awards. They also authorized the board to implement one or more reverse stock splits with an aggregate ratio up to 1‑for‑200.
Investors ratified RBSM LLP as auditor for the 2026 fiscal year, approved the full issuance of shares underlying a Lender Warrant under Nasdaq rules, and elected five directors to serve until the 2027 annual meeting. On the April 24, 2026 record date, 14,899,883 common shares were outstanding, with about 65% of votes represented at the meeting.
Synergy CHC Corp. received a non-compliance notice from Nasdaq after its common stock closed below $1.00 per share for 30 consecutive business days, violating the Nasdaq Capital Market minimum bid price rule.
The company has 180 calendar days, until November 11, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 straight business days. If it meets other Nasdaq listing standards, it may qualify for an additional 180-day grace period. Failing to regain compliance could lead to delisting, and management is monitoring the share price and may consider options such as a reverse stock split.
Synergy CHC Corp. reported weaker results for the quarter ended March 31, 2026. Revenue fell to $5.49 million from $8.17 million a year earlier as prior-year license revenue of $1.5 million did not repeat and online sales were hurt by out-of-stock issues in the Flat Tummy brand.
Despite over $650,000 in functional beverage revenue and an estimated beverage annual run rate above $4 million, profitability deteriorated. The company posted an operating loss of $0.57 million, a net loss of $2.57 million, and a basic and diluted loss per share of $0.23, versus net income of $0.88 million and earnings per share of $0.10 in the prior-year quarter.
Cash and cash equivalents declined to about $0.30 million as of March 31, 2026 from $2.6 million at December 31, 2025, and the company moved to a working capital deficit of $0.50 million. Total liabilities were $31.87 million against a stockholders’ deficit of $25.41 million. After quarter-end, Synergy raised approximately $2.7 million in gross proceeds through an at-the-market equity program to bolster liquidity.
Synergy CHC Corp. entered into an equity purchase agreement with Hudson Global Ventures giving the company the right, but not the obligation, to sell up to $36,000,000 of common stock over 24 months. Each draw must be at least $25,000 and no more than the lesser of $2,500,000 or 200% of recent average trading volume, with shares priced at 95% of specified market prices.
As consideration, Hudson received a warrant to buy 1,540,000 common shares at $0.01 per share, exercisable for five years, subject to a 4.99% beneficial ownership cap and an exchange cap tied to Nasdaq rules. Synergy agreed to register resale of shares under a registration rights agreement, avoid other equity lines and limit variable-rate financings, with certain rights of first refusal in favor of Hudson.
Synergy CHC Corp. amended its term loan, changing repayment timing, interest mechanics, pricing, covenants and default terms, and issued a new lender warrant. The amended agreement schedules principal payments of $175,000 on each of July 1, 2026 and October 1, 2026, then $525,000 on January 1, 2027 and $350,000 quarterly from April 1, 2027. If the company does not raise at least $10,000,000 of equity by September 30, 2026, the loan margin increases by 2.00% per year until that target is met. Interest due on March 2, 2026 must be paid in kind, and the company can elect to pay all or part of the April 1, 2026 interest in kind. New financial tests include minimum Consolidated Adjusted EBITDA of $500,000 for the quarter ended June 30, 2026 and $1,000,000 for the quarter ended September 30, 2026, plus revised senior net leverage thresholds, initially up to 20.00:1.00 for the quarter ended December 31, 2025. Equity issuance proceeds must follow a new waterfall where the first $6,000,000 can be retained and the next $4,000,000 must repay the term loan, with additional prepayments on amounts above $10,000,000 depending on leverage. The amendment also temporarily forces loans onto a reference rate and restricts future Term SOFR elections until at least $4,000,000 of principal has been repaid. In connection with the amendment, the company issued a 10‑year warrant giving a lender the right to buy 3,000,000 common shares at $0.00001 per share, exercisable only after a defined event of default and capped at 19.9% ownership unless stockholders approve a higher level by June 30, 2026.
Synergy CHC Corp. reported that on February 27, 2026, Gravity Pharma General Trading LLC terminated, ab initio, a Brand License Agreement originally signed on March 31, 2025 and later amended on June 30, 2025. The agreement had granted Gravity an exclusive license to sell and market certain FOCUSfactor and Flat Tummy Co. products in the United Arab Emirates and Turkey in exchange for an aggregate license fee of $2.9 million, which the company had previously recorded as revenue. Despite the termination, Synergy CHC states that it continues to pursue registration and marketing of these products in the same territories.
Synergy CHC Corp. furnished an 8-K to announce it issued a press release with financial and operating results for the quarter ended September 30, 2025. The company attached the press release as Exhibit 99.1, dated November 13, 2025, and noted the information is furnished, not filed, under the Exchange Act.
Synergy CHC Corp. reported that on September 22, 2025, board member Scott Woodburn resigned from the Board of Directors and all its committees in connection with his new role as the Company’s Head of Strategic Partnerships. The company states that his resignation was not due to any disagreement with the company, its board, or management regarding operations, policies, or practices.
The Board appointed Teresa Thompson to fill the resulting board vacancy and to serve on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. She will receive annual cash compensation of $25,000 and an annual equity award of $25,000 for her board service. Thompson previously served as a pharmacy OTC buyer for Costco Wholesale from September 1986 to June 2025, overseeing U.S. vitamins and supplements, and was appointed for her experience in the vitamin, supplement, and retail markets.
Synergy CHC Corp. entered a material underwriting agreement and sold 1,750,000 shares of common stock at $2.50 per share in a public offering, generating gross proceeds of $4.375 million before fees and expenses. Bancroft Capital, LLC acted as representative of the underwriters, who also received a 45-day option to purchase up to 262,500 additional shares to cover over-allotments at the same public price, less underwriting discounts and commissions.
The company plans to use the net proceeds for working capital and other general corporate purposes. It also issued Representative Warrants to Bancroft Capital, LLC and its designees to purchase up to 52,500 shares at an exercise price of $2.75 per share, subject to a 180-day lock-up and 180-day non-exercise period from the pricing date, with expirations staggered over the third, fourth, and fifth anniversaries of the closing date.
Synergy CHC Corp. filed a current report to share that it has released a press release about new business developments. The company notes that this press release is furnished as an exhibit under Regulation FD, which is designed to provide fair disclosure of important company information to the market.
The information in this section of the report, including the press release exhibit, is treated as "furnished" rather than "filed" under securities laws, which affects how certain legal liability provisions apply. Synergy CHC Corp.’s common stock trades on The Nasdaq Stock Market LLC under the symbol SNYR.
Synergy CHC Corp. reported that it has released its financial and operating results for the quarter ended June 30, 2025. The company disclosed these results through a press release dated August 14, 2025, which is included as Exhibit 99.1.
The disclosure is made under Item 2.02, which means the information in the press release is being furnished rather than formally filed under certain Exchange Act liability provisions. This 8-K informs investors where to find the full quarterly results while keeping the detailed financial data in the attached press release.